4.7 Article

Phosphorus-Based Dendrimer ABP Treats Neuroinflammation by Promoting IL-10-Producing CD4+ T Cells

Journal

BIOMACROMOLECULES
Volume 16, Issue 11, Pages 3425-3433

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.biomac.5b00643

Keywords

-

Funding

  1. Agence Nationale de la Recherche (grant DENDRI'MS) [ANR-RPIB-2011-005]
  2. Association pour la Recherche sur la Sclerose en Plaques (ARSEP)
  3. Institut National de la Sante et de la Recherche Medicale (INSERM)
  4. Centre National de la Recherche Scientifique (CNRS)
  5. University of Toulouse

Ask authors/readers for more resources

Dendrimers are polyfunctional nano-objects of perfectly defined structure that can provide innovative alternatives for the treatment of chronic inflammatory diseases, including multiple sclerosis (MS). To investigate the efficiency of a recently described amino-bis(methylene phosphonate)capped ABP dendrimer as a potential drug candidate for MS, we used the classical mouse model of MOG(35-55)-induced experimental autoimmune encephalomyelitis (EAR). Our study provides evidence that the ABP dendrirner prevents the development of EAR and inhibits the progression of established disease with a comparable therapeutic benefit as the approved treatment Fingolimod. We also show that the ABP dendrimer redirects the pathogenic myelin-specific CD4(+) T cell response toward IL-10 production.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available